[Veralipride in the treatment of hot flushes in the menopause].
Thirty-six menopausal women and 18 women with surgically-induced menopause were treated with a daily oral dose of 100 mg of veralipride for a period of 20 days followed by 10 days without therapy. Following 2 or 3 treatment periods, the drug was effective in 27 women from the first group and in 13 women from the second group. Six women had to discontinue therapy because of adverse effects. There was no significant variation in FSH or LH serum levels.
D000328:Adult; D004341:Drug Evaluation; D005260:Female; D005483:Flushing / Q000503:physiopathology / Q000628:therapy*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013469:Sulpiride; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C027429:veralipride
Le véralipride dans le traitement des bouffées de chaleur de la ménopause.